Publications by authors named "H Richly"
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFBackground: In uveal melanoma patients, short-term evaluation of treatment response to hepatic artery infusion chemotherapy (HAIC) using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is challenging due to the diffuse metastatic spread. As liver enlargement can frequently be observed, this study aims to compare RECIST 1.
View Article and Find Full Text PDFArticle Synopsis
- In this study, researchers looked at how two types of liver cancer cells in uveal melanoma patients affected their survival after getting a type of chemotherapy called HAIC.
- They studied 60 patients and found that most had the epithelioid pattern of cells, while fewer had the spindle cell pattern.
- The results showed that there was no big difference in how long patients lived after treatment, no matter which type of cancer cells they had.
Approximately every second patient with uveal melanoma develops distant metastases, with the liver as the predominant target organ. While the median survival after diagnosis of distant metastases is limited to a year, yet-to-be-defined subgroups of patients experience a more favorable outcome. Therefore, prognostic biomarkers could help identify distinct risk groups to guide patient counseling, therapeutic decision-making, and stratification of study populations.
View Article and Find Full Text PDFBackground: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.
Patients And Methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.
Results: Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.